IN2012DN03448A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03448A IN2012DN03448A IN3448DEN2012A IN2012DN03448A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A IN 3448DEN2012 A IN3448DEN2012 A IN 3448DEN2012A IN 2012DN03448 A IN2012DN03448 A IN 2012DN03448A
- Authority
- IN
- India
- Prior art keywords
- compounds
- methods
- administration
- preparing
- disclosed
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 208000018083 Bone metabolism disease Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 abstract 1
- -1 bisphosphonate cyclic acetal compounds Chemical class 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65746—Esters of oxyacids of phosphorus the molecule containing more than one cyclic phosphorus atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
- C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25488609P | 2009-10-26 | 2009-10-26 | |
| PCT/US2010/054124 WO2011056589A1 (en) | 2009-10-26 | 2010-10-26 | Bisphosphonate compounds for treating bone metabolism disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03448A true IN2012DN03448A (xx) | 2015-10-23 |
Family
ID=43478185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3448DEN2012 IN2012DN03448A (xx) | 2009-10-26 | 2010-10-26 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8314081B2 (xx) |
| EP (1) | EP2493905B1 (xx) |
| JP (1) | JP5850842B2 (xx) |
| CN (1) | CN102630227B (xx) |
| CA (1) | CA2778015C (xx) |
| IL (1) | IL219235A (xx) |
| IN (1) | IN2012DN03448A (xx) |
| MX (1) | MX2012004769A (xx) |
| SG (1) | SG10201406846XA (xx) |
| WO (1) | WO2011056589A1 (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2493905B1 (en) | 2009-10-26 | 2016-11-30 | Warner Chilcott Company, LLC | Bisphosphonate compounds for treating bone metabolism disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| BR112014016808B1 (pt) * | 2012-01-06 | 2022-01-11 | Anji Pharma (Us) Llc | Uso de um composto de biguanida para a fabricação de um medicamento para baixar os níveis de glicose no sangue e para o tratamento de um distúrbio do metabolismo de glicose |
| EP3105238A4 (en) | 2014-02-13 | 2017-11-08 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| WO2016003812A1 (en) | 2014-07-02 | 2016-01-07 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2043072B (en) | 1979-02-13 | 1983-11-23 | Symphar Sa | Diphosphonate compounds |
| DE3640938A1 (de) * | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
| JPH0699457B2 (ja) * | 1988-08-12 | 1994-12-07 | 山之内製薬株式会社 | ヘテロ環ビスフォスフォン酸誘導体およびその医薬 |
| US4990503A (en) | 1988-08-12 | 1991-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclic bisphosphonic acid derivatives |
| US5039699A (en) * | 1989-03-27 | 1991-08-13 | Lederle (Japan), Ltd. | Anti-peptic ulcer agent |
| US5227506A (en) | 1989-09-06 | 1993-07-13 | Merck & Co., Inc. | Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors |
| FI89366C (fi) * | 1990-12-20 | 1993-09-27 | Leiras Oy | Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat |
| US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
| CA2102303A1 (en) | 1991-06-19 | 1992-12-20 | Roy Allen Johnson | Dialkyl (dialkoxyphosphinyl) methyl phosphates as anti-inflammatory agents |
| JPH05239075A (ja) * | 1991-08-27 | 1993-09-17 | Eisai Co Ltd | 含リンイソプレノイド誘導体 |
| EP0541037A3 (en) * | 1991-11-06 | 1997-02-26 | Takeda Chemical Industries Ltd | Squalene synthetase inhibitory composition and use thereof |
| JPH06172372A (ja) * | 1991-11-06 | 1994-06-21 | Takeda Chem Ind Ltd | スクアレン合成酵素阻害剤およびその用途 |
| US5366965A (en) * | 1993-01-29 | 1994-11-22 | Boehringer Mannheim Gmbh | Regimen for treatment or prophylaxis of osteoporosis |
| US5719303A (en) | 1993-03-08 | 1998-02-17 | Eisai Co., Ltd. | Phosphonic acid derivatives |
| US5510517A (en) | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| EP0705834A1 (de) | 1994-07-27 | 1996-04-10 | Ciba-Geigy Ag | Azaaliphatisch Überbrückte Chinoxalin-2,3-dione |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US7358361B2 (en) | 2004-10-08 | 2008-04-15 | The Board Of Trustees Of The University Of Illinois | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
| US8012949B2 (en) * | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
| US7781418B2 (en) | 2006-12-14 | 2010-08-24 | Isis Innovation Ltd. | Composition for treating bone disorders |
| ES2478289T3 (es) | 2008-09-22 | 2014-07-21 | Isis Innovation Ltd | Bisfosfonatos de 5-azaindol |
| KR20110079813A (ko) | 2008-09-22 | 2011-07-08 | 아이시스 이노베이션 리미티드 | 이미다조〔1,2－α〕피리디닐 비스포스포네이트 |
| WO2010033980A2 (en) | 2008-09-22 | 2010-03-25 | Isis Innovation Ltd. | 4-azaindole bisphosphonates |
| EP2493905B1 (en) | 2009-10-26 | 2016-11-30 | Warner Chilcott Company, LLC | Bisphosphonate compounds for treating bone metabolism disorders |
-
2010
- 2010-10-26 EP EP10773501.1A patent/EP2493905B1/en not_active Not-in-force
- 2010-10-26 CN CN201080054060.1A patent/CN102630227B/zh active Active
- 2010-10-26 SG SG10201406846XA patent/SG10201406846XA/en unknown
- 2010-10-26 WO PCT/US2010/054124 patent/WO2011056589A1/en active Application Filing
- 2010-10-26 IN IN3448DEN2012 patent/IN2012DN03448A/en unknown
- 2010-10-26 JP JP2012536961A patent/JP5850842B2/ja active Active
- 2010-10-26 US US12/912,514 patent/US8314081B2/en active Active
- 2010-10-26 CA CA2778015A patent/CA2778015C/en active Active
- 2010-10-26 MX MX2012004769A patent/MX2012004769A/es active IP Right Grant
-
2012
- 2012-04-17 IL IL219235A patent/IL219235A/en active IP Right Grant
- 2012-10-12 US US13/650,785 patent/US8710215B2/en active Active
-
2014
- 2014-03-12 US US14/205,937 patent/US8822435B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102630227A (zh) | 2012-08-08 |
| IL219235A (en) | 2017-01-31 |
| US8710215B2 (en) | 2014-04-29 |
| MX2012004769A (es) | 2012-08-08 |
| US8822435B2 (en) | 2014-09-02 |
| CN102630227B (zh) | 2016-03-23 |
| JP2013508459A (ja) | 2013-03-07 |
| EP2493905B1 (en) | 2016-11-30 |
| IL219235A0 (en) | 2012-06-28 |
| US20140194389A1 (en) | 2014-07-10 |
| EP2493905A1 (en) | 2012-09-05 |
| US8314081B2 (en) | 2012-11-20 |
| US20130035482A1 (en) | 2013-02-07 |
| JP5850842B2 (ja) | 2016-02-03 |
| WO2011056589A1 (en) | 2011-05-12 |
| CA2778015A1 (en) | 2011-05-12 |
| US20110098251A1 (en) | 2011-04-28 |
| CA2778015C (en) | 2016-08-02 |
| SG10201406846XA (en) | 2014-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09805A (xx) | ||
| TN2012000126A1 (en) | Polycyclic compounds as lysophosphatidic acid receptor antagonists | |
| IN2012DN02177A (xx) | ||
| IN2012DN00754A (xx) | ||
| IN2014DN09804A (xx) | ||
| EA201290482A1 (ru) | Стабильные составы для лиофилизации терапевтических частиц | |
| WO2009135190A3 (en) | Therapeutic calcium phosphate particles and methods of making and using same | |
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| MX2013006040A (es) | Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
| MY166789A (en) | Arginine salts and their uses for the treatment of illnesses in the oral cavity | |
| MX2019000547A (es) | Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas. | |
| IN2012DN03448A (xx) | ||
| MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MY156302A (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES | |
| MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| BR112012026098A2 (pt) | métodos e composições para melhorar a osseointegração de implante. | |
| PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
| MX2013013649A (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
| MX342119B (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
| MX2009011577A (es) | Composiciones y metodos para distribucion de domperidona a traves de la mucosa. | |
| MX360235B (es) | Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo. |